Literature DB >> 27777293

Coronary Artery Bypass Graft Versus Percutaneous Coronary Intervention: Meds Matter: Impact of Adherence to Medical Therapy on Comparative Outcomes.

Paul Kurlansky1, Morley Herbert2, Syma Prince2, Michael Mack2.   

Abstract

BACKGROUND: Multiple studies have compared coronary artery bypass graft (CABG) with percutaneous coronary interventions (PCI) for coronary revascularization. There is considerable evidence that adherence to medical therapy can affect the outcomes of therapeutic interventions. However, the long-term influence of compliance with recommended medical therapy on the comparative outcomes of CABG versus PCI remains to be defined.
METHODS: All non-ST-segment-elevation myocardial infarction patients undergoing coronary revascularization in an 8-hospital network were followed for up to 8 years to determine medication history and major adverse cardiac events: all-cause mortality, nonfatal myocardial infarction, and reintervention. All mortalities were checked against the Social Security Death Index. Survival curves were derived with Kaplan-Meier methods; hazard ratios were calculated with the Cox proportional hazard model; and propensity score matching was used to account for differences in patient selection.
RESULTS: Among the 973 CABG and 2255 PCI patients, Kaplan-Meier major adverse cardiac event-free survival curves demonstrated a significant benefit for antiplatelet, lipid-lowering, and β-blocker therapy in both the CABG and PCI groups (P=0.001 for all 3 medications). Cox regression identified compliance with optimal medical therapy as a more powerful predictor of major adverse cardiac event-free survival than choice of therapy (hazard ratio for noncompliance=2.79; 95% confidence limits, 2.19-3.54; P<0.001; hazard ratio for PCI versus CABG=1.68, 95% confidence limits, 138-2.04; P<0.001). In propensity-matched patients, CABG outcomes were superior to PCI outcomes in patients nonadherent to optimal medical therapy (P=0.001) but were not different in patients adherent to optimal medical therapy (P=0.574).
CONCLUSIONS: Regardless of coronary revascularization strategy, medication adherence has a dramatic effect on long-term outcome. Among comparable patients who adhere to optimal medical therapy, outcomes of PCI and CABG may not differ; however, among nonadherent patients, CABG affords better major adverse cardiac event-free survival. Therefore, patient compliance with medical therapy may inform clinical decision making and should be incorporated into all future comparative studies of comparative coronary revascularization strategies.
© 2016 American Heart Association, Inc.

Entities:  

Keywords:  coronary artery bypass; coronary artery disease; drug therapy; percutaneous coronary intervention

Mesh:

Year:  2016        PMID: 27777293     DOI: 10.1161/CIRCULATIONAHA.115.021183

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  14 in total

1.  Optimal medical therapy is vital for patients with coronary artery disease and acute coronary syndromes regardless of revascularization strategy.

Authors:  Javaid Iqbal; Patrick W Serruys
Journal:  Ann Transl Med       Date:  2017-03

2.  Effects of statin therapy on platelet reactivity after percutaneous coronary revascularization in patients with acute coronary syndrome.

Authors:  Anna Toso; Stefano De Servi; Mario Leoncini; Dominick J Angiolillo; Paolo Calabrò; Federico Piscione; Marco Cattaneo; Diego Maffeo; Antonio Bartorelli; Cataldo Palmieri; Marco De Carlo; Davide Capodanno; Philippe Genereux; Francesco Bellandi; Chiara Barozzi; Luciana Tomasi; Diego Della Riva; Tullio Palmerini
Journal:  J Thromb Thrombolysis       Date:  2017-10       Impact factor: 2.300

3.  Hospital Variability Drives Inconsistency in Antiplatelet Use After Coronary Bypass.

Authors:  Jared P Beller; William Z Chancellor; J Hunter Mehaffey; Robert B Hawkins; Matthew R Byler; Alan M Speir; Mohammed A Quader; Andy C Kiser; Leora T Yarboro; Gorav Ailawadi; Nicholas R Teman
Journal:  Ann Thorac Surg       Date:  2020-02-11       Impact factor: 4.330

Review 4.  Acute Coronary Syndromes Among Patients with Prior Coronary Artery Bypass Surgery.

Authors:  Denada S Palm; Awa Drame; David J Moliterno; David Aguilar
Journal:  Curr Cardiol Rep       Date:  2022-09-12       Impact factor: 3.955

5.  Rediscovering Brazil: How We Prevent and Treat Cardiovascular Disease.

Authors:  Letícia Rodrigues Costa; Eduardo Vasconcelos Passos; Odilson Marcos Silvestre
Journal:  Arq Bras Cardiol       Date:  2021-01       Impact factor: 2.000

6.  Association of medication adherence and depression with the control of low-density lipoprotein cholesterol and blood pressure in patients at high cardiovascular risk.

Authors:  Julius L Katzmann; Felix Mahfoud; Michael Böhm; Martin Schulz; Ulrich Laufs
Journal:  Patient Prefer Adherence       Date:  2018-12-18       Impact factor: 2.711

7.  Secondary prevention medications after coronary artery bypass grafting and long-term survival: a population-based longitudinal study from the SWEDEHEART registry.

Authors:  Erik Björklund; Susanne J Nielsen; Emma C Hansson; Martin Karlsson; Andreas Wallinder; Andreas Martinsson; Hans Tygesen; Birgitta S Romlin; Carl Johan Malm; Aldina Pivodic; Anders Jeppsson
Journal:  Eur Heart J       Date:  2020-05-01       Impact factor: 29.983

8.  Optimal medical therapy with or without surgical revascularization and long-term outcomes in ischemic cardiomyopathy.

Authors:  Pedro S Farsky; Jennifer White; Hussein R Al-Khalidi; Carla A Sueta; Jean L Rouleau; Julio A Panza; Eric J Velazquez; Christopher M O'Connor
Journal:  J Thorac Cardiovasc Surg       Date:  2021-01-07       Impact factor: 6.439

9.  Socioeconomic Factors, Secondary Prevention Medication, and Long-Term Survival After Coronary Artery Bypass Grafting: A Population-Based Cohort Study From the SWEDEHEART Registry.

Authors:  Susanne J Nielsen; Martin Karlsson; Erik Björklund; Andreas Martinsson; Emma C Hansson; Carl Johan Malm; Aldina Pivodic; Anders Jeppsson
Journal:  J Am Heart Assoc       Date:  2020-03-02       Impact factor: 5.501

10.  The Arterial Revascularization Trial: It Is What It Is.

Authors:  Harold L Lazar
Journal:  J Am Heart Assoc       Date:  2019-11-22       Impact factor: 5.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.